Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastoma

Adding a novel anti-GD2 antibody (hu14.18K322A) to induction chemotherapy for children with newly diagnosed high-risk neuroblastoma yielded impressive survival outcomes and improved early responses versus historical benchmarks, investigators reported.

Read more: https://www.medpagetoday.com/hematologyoncology/othercancers/96035